Amgen to Present at Oppenheimer Healthcare Life Sciences conference
THOUSAND OAKS,Calif., Feb. 7, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) announced today its participation in the 35th Annual Oppenheimer Healthcare Life Sciences Conference.narimon Honarpour, senior vice president of global development at Amgen, will deliver a presentation at 11:20 a.m.ET on Wednesday, Feb. 12, 2025.
The webcast of the presentation will be accessible to members of the news media, investors, and the general public simultaneously via the internet.
Investors and interested parties can access the webcast, along with other selected presentations by Amgen management at various investor and medical conferences, on the company’s website at www.amgen.com under the Investors section.
details and Archive Access
Specific timing information, webcast availability, and webcast links can be found on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days following the event.
Amgen: A Leader in Biotechnology
Amgen, a leading biotech company with over four decades of experience, focuses on discovering, developing, manufacturing, and delivering innovative medicines for patients battling numerous serious diseases. The company played a pivotal role in establishing the biotechnology industry and continues to push the boundaries of innovation. Amgen leverages technology and human genetic data to advance its research.
Amgen’s robust pipeline of potential therapies builds upon its existing portfolio of medications targeting various conditions, including cancer, cardiovascular disease, osteoporosis, inflammatory diseases, and rare diseases.
Recognizing Amgen’s commitment to innovation, fast Company named the company one of the “World’s Most Innovative Companies” in 2024. Moreover, Forbes designated Amgen as one of “America’s Best Large employers” in the same year.
This conference presentation provides a valuable prospect for investors and stakeholders to gain insights into Amgen’s latest developments and its future direction in the field of biotechnology.
Amgen:
recognized as a Leading Healthcare Innovator
Amgen,a world-renowned biotechnology company,has solidified its prominent position in the global healthcare landscape. Recently recognized among a select group of renowned companies, Amgen has been included in the prestigious Dow Jones Industrial Average® and the Nasdaq-100 Index®. These inclusions underscore Amgen’s consistent performance, innovation, and contributions to the advancement of human health.
The Dow Jones industrial Average® comprises 30 leading companies representing diverse sectors of the U.S. economy, while the Nasdaq-100 Index® features the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. “The inclusion of Amgen in these esteemed indices is a testament to the dedication and hard work of our entire team,” said a representative from Amgen.”We are deeply honored to be recognized alongside other industry leaders and remain committed to delivering innovative therapies to patients worldwide.”
Amgen’s pioneering research and development efforts have resulted in groundbreaking therapies that have transformed the treatment of various diseases, including cancer, cardiovascular disease, and autoimmune disorders.
With a global reach and a relentless pursuit of scientific excellence,Amgen continues to push the boundaries of medicine,offering hope and improved quality of life to millions of people across the globe.
For more information about Amgen and its innovative therapies,visit Amgen.com and follow Amgen on social media platforms such as X (formerly Twitter), LinkedIn, Instagram, YouTube, and threads.
| CONTACT: | Amgen, Thousand Oaks |
| Elissa Snook, 609-251-1407 (media) | |
| Justin Claeys, 805-313-9775 (investors) |
Amgen to Present at Oppenheimer Healthcare Conference
The 35th Annual Oppenheimer Healthcare Conference will feature Amgen, a leading biotechnology company, as a presenter. The event is scheduled for February 20-23, 2025, in a hybrid format, allowing for both in-person and virtual attendance.
amgen plans to provide insights into its latest research and development initiatives during the conference. The company is highly likely to highlight its ongoing efforts in various therapeutic areas, such as oncology, immunology, and cardiovascular diseases.
Representatives from Amgen will engage with investors and other stakeholders, discussing the company’s strategic direction and long-term growth prospects. The conference provides a valuable platform for Amgen to showcase its innovations and strengthen relationships within the healthcare industry.
“We are excited to participate in the Oppenheimer Healthcare Conference and share our progress with the financial community and healthcare professionals,” said a spokesperson for Amgen.
Importance of Industry Conferences
Industry conferences like the Oppenheimer Healthcare Conference play a pivotal role in the biotech sector. They offer:
- Networking opportunities for companies to connect with investors, potential partners, and other industry leaders.
- Access to the latest research and trends, enabling companies to stay ahead of the curve and identify new opportunities.
- Publicity and exposure for companies to showcase their innovations and build brand awareness.
practical Applications for Investors
Investors can leverage these conferences to:
- Gain insights into the strategies and pipeline advancements of leading biotech companies.
- Conduct due diligence on specific companies of interest.
- Network with industry experts and analysts to gather valuable perspectives.
Amgen’s participation in the Oppenheimer Healthcare Conference underscores its commitment to transparency and engagement with the investment community. By sharing its latest developments and strategic vision, Amgen aims to further solidify its position as a leader in the biotechnology industry.
